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Abstract: Burkholderia cepacia complex (Bcc) is an opportunistic pathogen in cystic 
fibrosis patients which is inherently resistant to antimicrobial agents. The mechanisms of 
attachment and pathogenesis of Bcc, a group of 17 species, are poorly understood. The most 
commonly identified Bcc species in newly colonised patients, Burkholderia multivorans, 
continues to be acquired from the environment. Development of therapies which can 
prevent or reduce the risk of colonization on exposure to Bcc in the environment would be 
a better alternative to antimicrobial agents. Previously, it has been shown that Bcc strains 
bound to many glycolipid receptors on lung epithelia. Using a real-time PCR method to 
quantify the levels of binding of B. multivorans to the lung epithelial cells, we have 
examined glycoconjugate derivatives for their potential to inhibit host cell attachment. 
Bivalent lactosides previously shown to inhibit galectin binding significantly reduced the 
attachment of B. multivorans to CF lung epithelial cells at micromolar concentrations. This 
was in contrast to monosaccharides and lactose, which were only effective in the 
millimolar range. Development of glycoconjugate therapies such as these, which inhibit 
attachment to lung epithelial cells, represent an alternative means of preventing infection 
with inherently antimicrobially resistant pathogens such as B. multivorans. 
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1. Introduction 
Cystic fibrosis (CF) is a genetically inherited disease that is characterised by chronic lung infections 
which have a major impact on the mortality and quality of life of these patients. The majority of the 
opportunistic pathogens acquired by CF patients in later years are inherently antimicrobial resistant. 
These include Pseudomonas aeruginosa and members of the Burkholderia cepacia complex (Bcc). 
This latter pathogen is a group of 17 species, all of which are characterised by having multiple 
mechanisms of resistance to multiple antibiotics [1], and consequently this pathogen is rarely 
eradicated once a patient has been colonised. Although strict segregation measures have minimized 
patient-to-patient spread, Bcc, and increasingly B. multivorans, continues to be acquired from the 
environment [2]. Prevention of colonisation by topical application of biodegradable binding inhibition 
agents may represent a more effective approach than antibiotic therapy [3]. 
Previously, it has been shown that Bcc strains bind to many glycolipid receptors, including 
asialoGM1, asialoGM2 and globosides, on lung epithelia [4,5]. We have subsequently shown that 
intracellular invasion of B. multivorans into human lung cells relied on prior attachment to 
glycosphingolipids and not mucins [6]. However, the complete elucidation and identification of these 
receptors has yet to be determined. In the absence of clear identification of the actual receptors, 
screening a range of glycoconjugates for their potential to inhibit or compete with Bcc for binding 
sites, represents an alternative approach to the discovery of prophylactic treatments to prevent 
colonization. We have developed a rapid, reliable quantitative PCR technique for the identification of 
Bcc adhering to lung epithelial cells in vitro and have previously shown that millimolar concentrations 
of lactose could significantly decrease bacterial attachment to lung cells by over 50% [7]. 
Leyden et al., described the preparation of bivalent lactosides based on terephthalamides and 
glycophane scaffolds and demonstrated that they inhibited galectins, most readily galectin-3 [8]. Both 
flexible and rigid lactosides were potent at inhibiting binding of galectins to asialofetuin, while the 
more flexible bivalent lactosides blocked plant toxin binding to cells more efficiently than those with a 
more rigid scaffold. In this Communication, we further examine whether three of these galectin 
inhibitors could inhibit attachment of B. multivorans to lung epithelial cells.  
2. Results and Discussion 
The real-time PCR method has previously been developed and validated to quantitatively determine 
the attachment of B. multivorans to lung epithelial cells and its subsequent inhibition with simple 
sugars [7]. We chose two rigid and one flexible bivalent lactosides to investigate whether more 
complex glycoconjugates would be more effective inhibitors of bacterial attachment (Figure 1). RL1, 
the secondary amide was previously shown to have a constrained interlactose distance of 10.1 to  
10.4 Å [8]. RL2, the tertiary amide has an interlactose distance which is constrained between 7.2 and 
8.1 Å. In contrast, RL5 is very flexible with an interlactose distance which varies from 9 to 17 Å. 
Molecules 2012, 17 10067 
 
 
Bacteria were applied to lung epithelial cells in the absence and presence of glycoconjugates, allowed 
to attach and unattached bacteria washed off. The amount of remaining bacterial DNA was determined 
by quantitatitve real time PCR and normalized with human DNA using the glyceraldehyde phosphate 
dehydrogenase (GAPDH) gene. 
Figure 1. Chemical structure of bivalent lactosides used in this study. (a) RL1; (b) RL2 and (c) RL5. 
 
Preincubation of the bacteria with the flexible linker, RL5, strongly inhibited binding of  
B. multivorans to lung epithelial cells at concentrations from 9 to 90  (Figure 2). In contrast, the 
rigid lactoside, RL1, had little effect on binding of B. multivorans to lung cells at lower concentrations 
and indeed enhanced the amount of bacteria in contact with the cells by two-fold at the highest 
concentration tested. Although, the tertiary amide with the shortest interlactose distance, RL2, reduced 
attachment at low micromolar concentrations, it increased the levels of bacteria attached relative to 
uninhibited control by 2.5 fold at 47. In previous studies, we showed that lactose reduced 
attachment of B. multivorans to lung cells by 50% at concentrations of 20 mM, but had little effect at  
1 to 5 mM, while under the same conditions, galactose had no effect on bacterial attachment [7]. This 
study shows that the flexible bivalent lactoside is much more effective than lactose at inhibiting 
binding of B. multivorans to host cells. 
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Figure 2. Inhibition of binding of B. multivorans to lung epithelial cells. Bacteria were  
pre-incubated with lactosides for 30 min prior to infection of lung epithelial cells. Bars 
represent the fold change in binding of bacteria to lung epithelial cells relative to 
uninhibited solvent control. 
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The effect of the flexible lactoside at micromolar concentrations is promising in terms of future 
development of bacterial colonization inhibitors. Leyden et al. have previously shown that RL5 
resulted in marked inhibition of plant toxin binding to human lymphoblastoid cells, being more 
effective than lactose, and that the less flexible lactosides were less potent than that of lactose [8]. This 
study is in agreement with this, and again shows that the flexible bivalent lactoside is a potent inhibitor 
of bacterial binding. The increase in bacteria detected at higher concentrations of RL1 and RL2 was 
unexpected. It is possible that the conformation of these two lactosides allows the lactose moieties at 
either end bind to both bacteria and host cell simultaneously therefore acting as a bridge between the 
cells and enhancing their attachment. It is not known what affinity the lactosides have for host cells 
and this will be assessed in future studies. 
It has previously shown that another species in the Bcc, B. cenocepacia, expresses four soluble lectins 
with affinities for mannose or fucose, including a superlectin, BCL2-C, with dual specificities, fucose 
binding at the N-terminal domain with mannose and heptose affinity at the C-terminal domain [9]. 
However, the expression of lectin across other members of the Bcc, or in B. multivorans, specifically, 
has not been reported. Although B. cenocepacia is the most virulent of species within the Bcc,  
B. multivorans is currently being isolated more frequently from CF patients both in Europe and the US 
than B. cenocepacia [10]. A study by Baldwin et al. on B. multivorans isolates from industrial products 
and water environments showed that these were indistinguishable from clinical isolates, indicating that 
environmental sources may act as an important reservoir for infection of these species [11]. It is 
therefore important to be able to block the colonization of this species in CF patients. 
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Further studies are ongoing to evaluate several aspects of these glycoconjugates, including 
development of alternative carbohydrate moieties on the same scaffold, in addition to examining 
analogues of the flexible lactoside. In addition, the specificity of these glycoconjugates for inhibition 
of Burkholderia species needs to be assessed. This initial study shows promise for the future 
development of inhibitors of bacterial attachment in prevention of colonization by difficult to treat 
antimicrobial resistant pathogens. 
3. Experimental 
3.1. Preparation of Compounds 
The bivalent lactosides were prepared as outlined previously [8]. They were dissolved in DMSO 
which was subsequently diluted with Luria Bertani (LB) broth prior to analysis. 
3.2. Bacterial Strain and Epithelial Cells 
B. multivorans strain LMG13010, a member of the International Burkholderia cepacia working 
group panel was obtained from the BCCM/LMG University of Ghent (Ghent, Belgium) and routinely 
cultured on LB broth at 37 °C. Overnight cultures were grown to an OD of 0.6 and diluted. The lung 
epithelial cell line 16HBE14o− was kindly donated by Dr. Dieter Gruenert (University of California, 
San Francisco, San Francisco, CA, USA) and maintained in fibronectin-vitrogen coated flasks 
containing minimal essential medium (MEM) plus 10% (v/v) FBS as described previously [12]. For 
adhesion assays, 16HBE14o− cells were seeded on coated 24 well plates at 2.5 × 105 cells·mL−1 in 
supplemented MEM in the absence of antibiotics and incubated overnight at 37 °C in 5% CO2. The 
bacteria (~5 × 106 CFU) were then applied to the cells in MEM only and the plate was centrifuged at 
700 g for 5 min, to facilitate bacterial attachment. The plate was incubated at 37 °C in the presence of 
5% CO2 for 30 min and then washed vigorously three times with PBS to remove unbound bacteria.  
3.3. Relative Quantitation of B. multivorans 
The bacteria attached to the lung cells were detected by quantitative real time PCR method as 
described in Wright et al. [7]. DNA was extracted from the cells using a Wizard® Genomic DNA 
purification kit (Promega, Southampton, England) as outlined in the manufacturer’s instruction, to 
purify the template prior to amplification. The GAPDH gene was used as a reference to normalise the 
level of bacterial DNA present with that of human DNA. Forward and reverse primers to the  
B. multivorans recA gene and to the human GAPDH gene as outlined in [7] were used and amplification 
was carried out in a final volume of 20 µL containing 10 µL SYBR Green PCR Mix (Roche 
Diagnostics Ltd, Burgess Hill, England), 379 nM GAPDH primers or 190 nM RecA primers, and 4 µL 
of DNA. The plate was centrifuged briefly for 1 min at 700 g. Real-time PCR was carried out on 7300 
Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). The samples were amplified in 
triplicate as follows: 10 min at 95 °C for denaturation, followed by 40 cycles at 95 °C for 15 s and  
66 °C for 1 min. The data was collected during the 66 °C annealing/elongation phase. A dissociation 
step was carried out for melting curve analysis. The Pfaffl equation [13] was used to determine results 
incorporating the relative efficiencies of amplification of the target and reference genes. Real-time 
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PCR efficiencies (E) were acquired using a five-point standard curve with both GAPDH and recA gene 
primers to determine the slope. The corresponding efficiencies were calculated according to the 
following equation: Efficiency (E) = (10(−1/slope)). Using these calculated efficiencies, the relative 
amount of bacterial DNA was determined compared to human GAPDH based on the cycle threshold 
values of bacterial versus human genes [13]. 
3.4. Sugar Competition Assays 
Sterile solutions of bivalent lactosides (4.7 to 90 ) or lactose were prepared in MEM. An 
overnight culture of LMG13010 was grown to an OD600 nm of 0.6 and diluted to a final concentration of 
5 × 106 CFU·mL−1. Bacteria were pre-incubated with the sugar solutions for 30 min at 37 °C with 
gentle shaking and then applied to the 16HBE14o− cells. The plate was centrifuged at 700 g for 5 min 
and incubated at 37 °C in the presence of 5% CO2 for 30 min. Cells were washed vigorously three 
times with PBS to remove unbound bacteria. Real-time PCR was used for relative quantification and 
data for each sample in the presence of lactoside were compared with that of the 0.5% DMSO control. 
4. Conclusions 
The flexible bivalent lactoside showed promise in inhibition of attachment of B. multivorans to 
human lung cells. These encouraging results open the possibility to explore an anti-adhesion approach 
for Burkholderia infection. Little is known about the structural motifs that regulate adhesion in this 
pathogen, so, at present, it is difficult to carry out “rational design” for specific ligands. Hence we are 
continuing to investigate structurally diverse synthetic glycoconjugates, and the influence of the 
presentation of the carbohydrates in the different scaffolds in inhibiting/promoting adhesion may help 
to elucidate the structural basis of these processes. 
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